Study design
The present study was planned in the prospective, double-blind, randomized controlled study design, and Institutional Review Board approval (07-2021/02) of Karamanoglu Mehmetbey University Faculty of Medicine, Turkey was obtained on October 11, 2021. The study was registered prospectively at clinicaltrials.gov (NCT0510812) on November 4, 2021 and designed in accordance with the principles set out in the Declaration of Helsinki. Written informed consent was obtained from all participants regarding the interventions and enrollment in the study. The Consolidated Standards for Reporting Studies (CONSORT) checklist was used for patient enrollment (Fig. 